Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Safety and efficacy of sacubitril/valsartan in patient with heart failure

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: RAY, Chin (Chang Gung Memorial Hospital, Linkou, Taiwan, Department of Pharmacy)
  • Co-author(s): Chin-Ying Ray
    Tzu-Cheng Tsai
    Shin-Tarng Deng
  • Abstract:

    Background

    Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization and high mortality rate within 5 years.According to the PARADIGM-HF study, sacubitril/valsartan (Entresto) reduce cardiovascular risk by 20%. However, clinicians are still worried whether this medicine will cause..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses